Nadia Dac
Corporate Officer/Principal bij OMEROS CORPORATION
Profiel
Nadia Dac currently works at Omeros Corp., as Chief Commercial Officer from 2021.
Ms. Dac also formerly worked at Auxilium Pharmaceuticals LLC, as Vice President-Marketing from 2013 to 2014, AbbVie, Inc., as VP-Global Specialty Commercial Development from 2014 to 2019, Novartis AG, as VP-Neuroscience Professional Relations from 2009 to 2013, and Lundbeck Seattle BioPharmaceuticals, Inc., as Chief Commercial Officer from 2019 to 2020.
Ms. Dac received her undergraduate degree from Rutgers State University of New Jersey.
Actieve functies van Nadia Dac
| Bedrijven | Functie | Begin |
|---|---|---|
| OMEROS CORPORATION | Corporate Officer/Principal | 26-01-2021 |
Eerdere bekende functies van Nadia Dac
| Bedrijven | Functie | Einde |
|---|---|---|
| ALDER BIOPHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-06-2020 |
| ABBVIE INC. | Corporate Officer/Principal | 01-03-2019 |
| AUXILIUM PHARMACEUTICALS, INC. | Sales & Marketing | 01-09-2014 |
| NOVARTIS AG | Corporate Officer/Principal | 01-01-2013 |
Opleiding van Nadia Dac
| Rutgers State University of New Jersey | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| OMEROS CORPORATION | Health Technology |
| ABBVIE INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Auxilium Pharmaceuticals LLC
 Auxilium Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Auxilium Pharmaceuticals LLC develops and markets pharmaceutical products. It specializes in men's healthcare area and has product portfolio and pipeline in orthopedics, dermatology and other therapeutic areas. The firm products include edex, Osbon, ErecAid, STENDRA, TESTOPEL, XIAFLEX and Testim. The company was founded by Gerri A. Henwood and Jane Holmes Hollingsworth in 1999 and is headquartered in Chesterbrook, PA. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
